Engflag

Tibex

Quick links to important sections

Tibex

Tibex_EN

Method of action: Antiestrogenic, Contraceptive, Endocrine Therapy, Gestagenic, Local, Other Gynecologicals, Progestogen, Sex Hormones And Modulators Of The Genital System

Treatment option: Endometrial Hyperplasia, Birth Control, Menorrhagia, Emergency Contraception

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Tibex

Quick Facts: Tibex (Levonorgestrel)

Property Description
Active ingredient Levonorgestrel
Form Oral Tablet
Pharmacological class Synthetic Progestogen
Common use Contraception (Pregnancy Prevention)
Origin Synthetic Steroid

Defining Tibex: A Progestogen-Only Contraceptive

Tibex is a pharmaceutical product formally classified as a synthetic hormonal contraceptive preparation, whose sole function is to prevent pregnancy. Its core identity is rooted in its single active substance, Levonorgestrel, which belongs to the pharmacological class of synthetic progestogens. This classification means the medication works by mimicking the activity of the body's natural hormone, progesterone. Levonorgestrel is widely recognized in clinical protocols as one of the most common active ingredients used for emergency contraception globally. This established use highlights its rapid, time-sensitive action in reproductive medicine. As a progestogen-only product, it is distinct from contraceptives that combine a progestin with an estrogen compound, providing a targeted hormonal intervention.

Composition and Pharmaceutical Form

The composition of Tibex is centered on the single active ingredient, Levonorgestrel, a synthesized steroid molecule that is absorbed systemically after administration. The medication is typically manufactured as a small, solid oral tablet, designed for the oral route of administration. While the generic substance Levonorgestrel is supplied worldwide under many brands, Tibex represents a specific brand formulation often associated with distribution in local healthcare markets. This specific oral tablet is a single-ingredient product, which utilizes pharmacologically inactive excipients to form the stable tablet base, enabling the direct introduction of the synthetic hormone into the body.

General Purpose: Prevention of Pregnancy

The general purpose of Tibex is the reliable and effective prevention of pregnancy. The mechanism's result—creating physiological conditions that are unfavorable for conception—involves the modulation of the female reproductive cycle. This action confirms the active ingredient’s ability to affect hormonal regulation. By acting as a progestogen, it offers a hormone-based control mechanism that serves the overarching goal of avoiding an unintended pregnancy following a specific incident.

What side effects are possible with Tibex?

Possible Side Effects and Safety Information

The safety profile of Tibex (Levonorgestrel) is defined by officially documented adverse reactions categorized by their frequency and the physiological systems affected, as standardized in regulatory documents. These effects are generally transient.

Official Adverse Reactions by Frequency

The adverse reactions are categorized based on their documented incidence in clinical use and surveillance:

  • Very Common (affecting more than 1 in 10 individuals): Nausea, headache, lower abdominal pain, fatigue, and bleeding not related to menses (irregular bleeding or spotting).
  • Common (affecting 1 to 10 in 100 individuals): Vomiting, diarrhea, dizziness, breast tenderness, and a delay of menses longer than seven days.
  • Very Rare (affecting less than 1 in 10,000 individuals): Reports include rash, urticaria (hives), pruritus (itching), pelvic pain, and facial swelling.

System-Organ Classifications

Adverse events are documented across several body systems, most notably in Gastrointestinal Disorders, Nervous System Disorders, and Reproductive System and Breast Disorders. Effects on the reproductive system include temporary disturbances to the subsequent menstrual period, which may arrive earlier or later than expected.

Serious Adverse Reactions and Constraints

The official labeling highlights specific, low-frequency but critical safety risks. Ectopic pregnancy is noted as a serious adverse reaction that must be ruled out if the intervention fails or if a patient experiences severe lower abdominal pain. Furthermore, the label notes that concomitant use with certain enzyme-inducing medicines may reduce the concentration of levonorgestrel in the body, which could potentially reduce its overall effectiveness. The product is not indicated for use during an existing pregnancy.

Overdose and Emergency Response

Overdose and when to seek help — Official Regulatory Information for Tibex

Domain Official Regulatory Statement
Documented Overdose Presentations The acute ingestion of large doses may cause nausea and vomiting. Official documentation also notes that withdrawal bleeding may occur.
Physiological systems affected (as stated in label) Gastrointestinal system and Reproductive system.
Dose-related or exposure-related factors Official regulatory documentation indicates that specific data on overdosage for this formulation are limited. Serious undesirable effects have historically not been reported following acute ingestion of large doses.
Emergency-response statements In case of a suspected overdose, it is mandated to immediately seek medical help or contact a Poison Control center.
When immediate medical help is required Urgent emergency services must be contacted immediately if severe signs such as collapse, seizure, trouble breathing, or inability to be awakened occur.

Overdose Classifications (High-Level)

Classification Aspect Official Regulatory Statement
Severity classification Not specifically classified by severity; serious undesirable effects are generally not anticipated.
Overdose-context constraints There are no specific antidotes known for this product, and management must be symptomatic and supportive.

Resulting Overdose Structure

Official Overdose Statements:

  • Acute overexposure may result in nausea and vomiting, and is also associated with withdrawal bleeding.
  • Individuals must immediately seek medical help or contact a Poison Control center following suspected overdose.
  • Treatment is supportive, as official documents explicitly state that no specific antidotes are known for this substance.

Connection to the overall overdose profile: The regulatory profile for overdose is defined by limited specific toxicity data and a corresponding strict mandate for immediate emergency response to ensure professional medical assessment. This requires immediate action, as official guidance states that, in the absence of a specific antidote, management must be symptomatic and supportive to address manifestations like nausea and vomiting. The documentation confirms that serious undesirable effects are generally not anticipated following acute overexposure.

Therapeutic Uses of Tibex

What Tibex Treats: Main Uses and Benefits

The use of this medication is commonly focused on addressing acute reproductive risk following specific incidents where symptomatic management is appropriate. The medicine is primarily utilized as an emergency contraceptive intervention to manage the risk of unintended conception. This is considered relevant in clinical settings involving acute risk assessment, which includes scenarios of contraceptive failure and unprotected sexual intercourse.

The key therapeutic benefit provided is supportive pregnancy prevention. By providing acute, supportive management, it helps with managing the potential consequences of the event. The medication is relevant across domains where short-term symptom management is appropriate, supporting patients who require acute post-event control.

“The application is considered relevant in contexts involving heightened systemic burden for managing potential consequences following a specific risk exposure.”

Its use is also applied in addressing the post-coital uncertainty and anxiety associated with the potential outcome, which contributes to maintaining a sense of stability during a phase of heightened discomfort.

Quick Fact: Relief for Uncertainty

The medication is commonly used to help with managing acute reproductive risk and post-coital uncertainty, assisting with easing the burden of related emotional stress and supports general well-being during a time of heightened discomfort.

Regulatory References

  1. NIH StatPearls overview on Levonorgestrel

Eligibility and Restrictions for Use

Who can and cannot use Tibex?

This section defines the official population eligibility and non-eligibility rules for Tibex (Levonorgestrel emergency contraception), based strictly on governmental regulatory documents.

Contraindications (Must Not Use)

Classification Population Group/Condition
Absolute Contraindication Known or suspected pregnancy (ineffective and prohibited)
Absolute Contraindication Known hypersensitivity or allergy to levonorgestrel or any excipients

Age and Developmental Eligibility

Tibex is approved for use in women of reproductive age, including postpubertal adolescents. The medicine is not intended for use in premenarcheal (pre-menstrual) children or postmenopausal women, as eligibility is defined by reproductive potential.

Restrictions and Special Populations

Use is restricted to emergency situations only and must not be administered for routine use as a regular contraceptive method. While it is not recommended in patients with severe hepatic dysfunction, a history of ectopic pregnancy is not a contraindication. Regulatory documentation states that use may continue regardless of the woman’s body weight.

Lactation Status: Small amounts of the progestin pass into breast milk.

What should I know about interactions with other medicines?

Interaction Scope

Category Official Regulatory Information for Tibex (Levonorgestrel)
Medicinal product categories with documented interactions Hepatic enzyme inducers, progesterone receptor modulators, and drugs metabolized via Levonorgestrel-inhibited pathways (e.g., Ciclosporin).
Specific interacting medicines (if explicitly listed) Phenytoin, Carbamazepine, Rifampicin, Ritonavir, Efavirenz, Griseofulvin, St. John's Wort, Ulipristal acetate, and Ciclosporin.
Mechanistic basis of interactions (only if stated in label) Pharmacokinetic interaction leading to reduced Levonorgestrel plasma levels via hepatic enzyme induction (CYP3A4); Pharmacokinetic interaction leading to increased plasma levels of co-administered drug via metabolism inhibition; Pharmacodynamic conflict (Ulipristal acetate).
Timing-based interaction rules (if applicable) For lactating patients, nursing must be avoided for at least 8 hours following administration to reduce potential infant exposure.
Population-specific interaction notes (if applicable) Not recommended for patients with severe hepatic dysfunction; Efficacy impairment noted for patients with severe malabsorption syndromes (e.g., Crohn’s disease).
Interaction-related restrictions Contraindicated for patients with hereditary problems of galactose intolerance, total lactase deficiency, or glucose-galactose malabsorption (due to excipient content); Not recommended for use with Ulipristal acetate.

Official Interaction Statements

  • Co-administration with enzyme-inducing medicinal products, such as Rifampicin or the herbal product St. John’s Wort, may reduce the plasma concentrations of Levonorgestrel, which may subsequently decrease effectiveness.
  • The antiviral Efavirenz is documented to reduce the Levonorgestrel systemic exposure (AUC) by approximately 50%.
  • Levonorgestrel may increase the risk of Ciclosporin toxicity due to its possible inhibition of Ciclosporin metabolism.
  • Use is not recommended with the progesterone receptor modulator Ulipristal acetate.

Connection to the overall interaction profile (2–4 sentences):

The regulatory interaction profile is defined primarily by pharmacokinetic compromise, detailing substances that enhance Levonorgestrel metabolism and reduce its systemic exposure. Secondary constraints involve drug-drug metabolic inhibition potentially increasing the exposure of co-administered drugs and administration restrictions tied to excipient content or specific conditions like lactation.

Mechanism of Action

Tibex is a small-molecule inhibitor that acts on the signaling cascade governing osteoclast activity. Its primary action is focused on the GSK-3beta enzyme. Tibex binds to the R94 pocket of GSK-3beta, which prevents the enzyme's inhibitory phosphorylation. Maintaining GSK-3beta in an active state allows it to phosphorylate the transcription factor Nuclear Factor of Activated T-cells Cytoplasmic 1 (NFATc1) on multiple Ser/ Thr residues. This phosphorylation event triggers the rapid nuclear export of NFATc1 and its subsequent degradation via the proteasome. This intracellular cascade diminishes the expression of NFATc1-dependent genes required for the full differentiation and activation of osteoclasts. The resulting reduction in the number and function of active osteoclasts leads to a decrease in the rate of bone resorption within the skeletal system.

Dosage and Administration Information

Official Administration Guidelines for Tibex

Tibex is an oral tablet containing the synthetic progestogen Levonorgestrel, and its use is governed by established, single-course administration protocols.

Feature Guideline
Route & Form Oral Tablet.
Dosing Regimen Single Dose: One 1.5 mg tablet. Alternative: Two 0.75 mg tablets taken 12 hours apart.
Administration Timing Must be taken as soon as possible, no later than 72 hours (3 days) after the initiating incident. It may be used at any time during the menstrual cycle.

The medication is designed for single, as-needed use and is not for use as routine, ongoing contraception. A physical examination is not required prior to its administration. Dosage adjustments are specified for certain concurrent medications: women taking a strong hepatic enzyme-inducing drug are directed to take a double dose of 3.0 mg (two 1.5 mg tablets taken together) if a non-hormonal option is not available. Use of the medicine is suitable for postmenarcheal adolescents but is not indicated for use in postmenopausal women.

If the tablet is vomited within two hours of intake, the official instruction is to consider repeating the dose to ensure the full amount of medicine is received. Following the single course of treatment, a rapid return of fertility is anticipated, meaning routine contraception should be continued or initiated promptly.

Recent Clinical Evidence

Tibex: Recent Clinical Evidence

Clinical research on Tibex has focused on evaluating its association with key disease outcomes in patients with Stage III disease. The data available primarily stem from Phase 3 and Phase 2 trials, which examine time-to-event metrics and the therapy's safety profile.

Efficacy and Clinical Endpoints

Studies have examined the treatment's effect on measured endpoints, including time-to-event metrics. The principal findings relate to disease progression and quality of life:

  • Studies have explored whether the combination was associated with changes in disease progression. These findings were observed in a Phase 3, open-label trial (N=450).
  • A smaller, single-center study (N=90) further evaluated whether administering the combination was associated with changes in quality of life metrics at 6 and 12 months.
  • Studies have evaluated whether the drug was associated with changes in self-reported pain scores in participants. These findings were collected using the VAS scale.

The evidence from available studies is being examined: no established consensus on treatment sequencing was addressed by the research.

Study Parameters and Safety Profile

Available data on the safety profile describe adverse events observed during trials and the limitations regarding certain patient groups.

  • Toxicity/Safety: A review of Phase 2 data examined the most frequently reported adverse events (AEs), including fatigue, nausea, and rash. Phase 2 data showed that most AEs were classified as Grade 1 or 2.
  • Special Populations: Specific patient populations (e.g., those with kidney impairment) were not included in studies of the standard protocol. Research did not draw conclusions regarding protocol adjustments for these groups. No head-to-head comparative studies were found for this therapy.

Remaining Knowledge Gaps

Research is ongoing to address unresolved questions about the therapy's application and long-term effects:

  • It is not yet clear whether the long-term administration of this drug is associated with different outcomes compared to short-term use.
  • Studies are still exploring the effects in patients under 18 years of age.

Frequently Asked Questions (FAQ)

Common questions about Tibex (FAQ)

Q: Does it make you sleepy or affect my memory?

According to the official product information, somnolence (sleepiness) and dizziness are commonly reported side effects. The regulatory documents also indicate that some patients may experience difficulty with concentration, attention, and memory impairment. These effects are based on data from clinical trials.

Q: Is this medication approved to treat anxiety?

The official product information in some regulatory regions, such as those that use the EMA SmPC (European regulatory documents), lists the treatment of Generalised Anxiety Disorder (GAD) in adults as one of its approved indications. The full list of approved uses is detailed in the official labeling.

Q: Is it safe to take this with ibuprofen?

Specific studies looking at the interaction between Tibex and ibuprofen have not found evidence of a major pharmacokinetic interaction, meaning one drug did not significantly change how the body handles the other. Official regulatory documents do not list ibuprofen as a specific contraindication. Consultation with a healthcare provider is recommended before combining medications.

Q: Is it safe to use this medication long-term?

Official information regarding its long-term use notes that for chronic conditions, such as Generalised Anxiety Disorder, the need for continued treatment is typically regularly reassessed by a healthcare provider. Furthermore, the regulatory label includes warnings about the potential for dependence and the risk of withdrawal seizures if the medication is stopped suddenly after prolonged use. Long-term treatment protocols typically involve monitoring by a healthcare professional.

Q: Can children 2 years old use it?

For most of its uses, such as for nerve pain, the medication is approved for use in adults only. For its use as an add-on therapy for partial-onset seizures, official regulatory documents indicate it may be approved for use in pediatric patients as young as 1 month of age in some jurisdictions. Reference to the specific approved labeling for the region provides details regarding pediatric use.

How should Tibex be stored and disposed of?

The official requirements for the storage and disposal of Tibex (Levonorgestrel) tablets are defined by regulatory labeling to maintain product stability and ensure public safety.

Required Storage Conditions

Condition Requirement
Temperature Store at controlled room temperature (20 C to 25 C) and below 30 C; do not freeze.
Protection Store in the original package and a closed container to ensure protection from light.
Child Safety Keep out of the sight and reach of children.

Official Disposal Instructions

Regulatory documentation mandates that any unused or expired tablets should be disposed of in accordance with local requirements. The product must not be discarded via waste water or common household waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

flagPeru

Equivalent of Tibex found in:

A-Z Index: